Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
8(80.0%)
Phase 2
1(10.0%)
Phase 3
1(10.0%)
10Total
Phase 1(8)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT04851613Phase 3Active Not Recruiting

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Role: lead

NCT07230496Phase 1Recruiting

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants

Role: lead

NCT06493084Phase 1Recruiting

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

Role: lead

NCT06908707Phase 1Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

Role: lead

NCT05383482Phase 1Completed

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Role: lead

NCT03843918Phase 1Terminated

A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

Role: lead

NCT04374630Phase 2Completed

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Role: lead

NCT04060394Phase 1Completed

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Role: lead

NCT05390710Phase 1Completed

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

Role: lead

NCT05489744Phase 1Completed

Human Mass Balance and Biotransformation Study of [14C]Afuresertib

Role: lead

All 10 trials loaded